Pappas S C, Hoofnagle J H, Young N, Straus S E, Jones E A
J Med Virol. 1985 Jan;15(1):1-9. doi: 10.1002/jmv.1890150102.
Five patients with chronic non-A, non-B hepatitis were entered into a pilot therapeutic study of the antiviral agent acyclovir [9-(2-hydroxyethoxymethyl)guanine]. Each patient received acyclovir by slow intravenous infusion in a dosage of 5 mg/kg every 8 hr for 10 days. During therapy, serum aminotransferase levels decreased by more than 50% in two patients, remained unchanged in two patients, and rose (by 32%) in the final patient. The two patients whose serum aminotransferase levels decreased during acyclovir treatment subsequently received a second course of drug using a higher dose (10 mg/kg every 8 hr for 10 days). Serum aminotransferase levels rose in both patients (by 54% and 121%) during the second course of therapy. Acyclovir was well tolerated in these patients, and there were no symptoms or signs attributable to drug toxicity during or after treatment. During a subsequent 12-month follow-up period, none of the five patients has manifested either a clinical or serum biochemical improvement in their chronic liver disease. Spontaneous fluctuations in serum aminotransferase levels unrelated to acyclovir therapy were noted in three of the five patients. These findings suggest that a short course of acyclovir does not have any appreciable long-term beneficial effect on the course of chronic non-A, non-B hepatitis.
五名慢性非甲非乙型肝炎患者进入了抗病毒药物阿昔洛韦[9-(2-羟乙氧甲基)鸟嘌呤]的初步治疗研究。每位患者每8小时接受一次5毫克/千克剂量的阿昔洛韦缓慢静脉输注，持续10天。治疗期间，两名患者的血清转氨酶水平下降超过50%，两名患者的血清转氨酶水平保持不变，最后一名患者的血清转氨酶水平上升（32%）。在阿昔洛韦治疗期间血清转氨酶水平下降的两名患者随后接受了第二个疗程的药物治疗，使用更高剂量（每8小时10毫克/千克，持续10天）。在第二个疗程中，两名患者的血清转氨酶水平均上升（分别上升54%和121%）。这些患者对阿昔洛韦耐受性良好，治疗期间或治疗后均无药物毒性的症状或体征。在随后的12个月随访期内，五名患者中没有一人的慢性肝病在临床或血清生化方面有所改善。五名患者中有三名出现了与阿昔洛韦治疗无关的血清转氨酶水平自发波动。这些发现表明，短期使用阿昔洛韦对慢性非甲非乙型肝炎的病程没有任何明显的长期有益影响。
